LA JOLLA–Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced disease. It sounds like science fiction, but Salk scientists have gotten one step closer to creating such a drug by customizing a powerful defense system used by many bacteria and training this scissor-like machinery to recognize the HIV virus.
LA JOLLA–Tony Hunter, professor and director of the Salk Institute Cancer Center, in La Jolla, California, has received the BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category for “carving out the path that led to the development of a new class of successful cancer drugs.”
LA JOLLA–Walking across an icy parking lot in winter–and remaining upright–takes intense concentration. But a new discovery suggests that much of the balancing act that our bodies perform when faced with such a task happens unconsciously, thanks to a cluster of neurons in our spinal cord that function as a “mini-brain” to integrate sensory information and make the necessary adjustments to our muscles so that we don’t slip and fall.
LA JOLLA–Salk researchers have developed an entirely new type of pill that tricks the body into thinking it has consumed calories, causing it to burn fat. The compound effectively stopped weight gain, lowered cholesterol, controlled blood sugar and minimized inflammation in mice, making it an excellent candidate for a rapid transition into human clinical trials.
LA JOLLA–You’ve misplaced your cell phone. You start by scanning where you remember leaving it: on your bureau. You check and double-check the bureau before expanding your search around and below the bureau. Eventually, you switch from this local area to a more global one, widening your search to the rest of your room and beyond.
LA JOLLA–The Salk Institute is pleased to announce the election of Richard A. Heyman, PhD, to its Board of Trustees. Heyman currently serves as CEO of Seragon Pharmaceuticals, a San Diego-based biotech company that he co-founded in August 2013. Seragon develops selective estrogen receptor degraders (SERDs), which are being used for the treatment of breast cancer.
LA JOLLA–Pain typically has a clear cause–but not always. When a person touches something hot or bumps into a sharp object, it’s no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony.
LA JOLLA–These days, with the abundance of artificial light, TV, tablets and smartphones, adults and children alike are burning the midnight oil. What they are not burning is calories: with later bedtimes comes the tendency to eat.
LA JOLLA–Taking a single snapshot of all the bacteria that live in a mouse’s–or person’s–stomach and intestines can capture the health of the organism’s digestive system and even their risk of developing immune diseases and cancers. But it might take more than one snapshot to get a full picture, Salk researchers have discovered.
Janelle Ayres, Salk assistant professor in the Nomis Foundation Laboratories for Immunobiology and Microbial Pathogenesis, has been selected to receive the prestigious Ray Thomas Edwards Foundation Career Development Award. Only one three-year grant is conferred annually, aiming to foster the development of a promising early career biomedical researcher in San Diego County and to help him or her make the transition to becoming an independent investigator.
LA JOLLA–For decades, researchers have struggled to translate basic scientific discoveries about cancer into therapeutics that effectively–and with minimal side effects–shrink a tumor.
LA JOLLA–Scientists at the Salk Institute have discovered a powerful one-two punch for countering a common genetic mutation that often leads to drug-resistant cancers. The dual-drug therapy–with analogs already in use for other diseases–doubled the survival rate of mice with lung cancer and halted cancer in pancreatic cells.
LA JOLLA–Researchers at the Salk Institute have healed injured hearts of living mice by reactivating long dormant molecular machinery found in the animals’ cells, a finding that could help pave the way to new therapies for heart disorders in humans.
LA JOLLA–Like a slumbering dragon, HIV can lay dormant in a person’s cells for years, evading medical treatments only to wake up and strike at a later time, quickly replicating itself and destroying the immune system.
LA JOLLA–Like a colony of bacteria or species of animals, cancer cells within a tumor must evolve to survive. A dose of chemotherapy may kill hundreds of thousands of cancer cells, for example, but a single cell with a unique mutation can survive and quickly generate a new batch of drug-resistant cells, making cancer hard to combat.
LA JOLLA–Scientists at the Salk Institute and Beth Israel Deaconess Medical Center (BIDMC) in Boston have discovered a new class of molecules–produced in human and mouse fat–that protects against diabetes.
LA JOLLA–Scientists at the Salk Institute have scored a rare hat trick with a third assistant professor from the Waitt Advanced Biophotonics Center being named a recipient of the prestigious National Institutes of Health (NIH) Director’s New Innovator Award.
LA JOLLA—Joseph Ecker, a Salk professor and Howard Hughes Medical Institute investigator, and Margarita Behrens, Salk staff scientist, have been named recipients in the 2014 round of grants from the National Institutes of Health (NIH) through the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative for leading-edge work in neuroscience. The grant, announced September 30, provides more than $3 million in funding to the Salk scientists over three years.
LA JOLLA–A synthetic derivative of vitamin D was found by Salk Institute researchers to collapse the barrier of cells shielding pancreatic tumors, making this seemingly impenetrable cancer much more susceptible to therapeutic drugs.
